Chengdu Easton Biopharmaceuticals (688513.SH): Nicardipine hydrochloride injection and others are expected to be selected for the national centralized drug procurement.

Chengdu Easton Biopharmaceuticals (688513.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., participated in the bidding organized by the National Organization for Drug Procurement Office for the twelfth batch of national centralized drug procurement. According to the "Public Announcement of the Proposed Selected Results for the 12th Batch of National Organized Drug Centralized Volume Procurement" published by the procurement office that evening, the hydrochloride injection of Nicardipine and the Bisoprolol/Amlodipine tablets from the company and its wholly-owned subsidiary are proposed to be selected in this centralized procurement. The procurement cycle for this centralized procurement will last from the actual execution date of the selected results until December 31, 2029. During this cycle, medical institutions will prioritize the use of the drugs selected in this centralized procurement and ensure that the agreed procurement volume is met. It is expected to begin implementation in the fourth quarter of 2026, and will not affect the company's operating performance for the first half of 2026. The selected prices for this procurement have decreased to a certain extent compared to the original sales prices. If the company subsequently signs and executes procurement contracts, it will be beneficial for further expanding the sales volume of relevant products, increasing cooperation channels, promoting the development of related products in the domestic market, and enhancing the accessibility of the drugs.